BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28

• Genetown

  Blue Earth Diagnostics Announces Presentation at Upcoming ASCO 2018 Genitourinary Cancers Symposium on Fluciclovine (18F) PET/CT Impact on Clinical Management of Recurrent Prostate Cancer

  Blue Earth Diagnostics announced the upcoming presentation of initial results from the FALCON clinical trial (NCT02578940) of fluciclovine (18F) PET/CT, evaluating its impact on patient management in biochemically recurrent prostate cancer patients scheduled for salvage treatment with curative intent.

  February 5, 2018

   · 

  5 min read
• 

  Drug Development

  EyeGate Implodes as Eye Drug Flunks Phase II Test

  EGP-437 demonstrated better clinical performance than vehicle control but did not meet its co-primary endpoints.

  February 5, 2018

   · 

  5 min read
• Business

  Minerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent Director

  Dr. Luthringer, as Executive Chairman of the Board and Chief Executive Officer of Minerva, will continue his close involvement with Minerva’s R&D team in the execution of five late stage clinical trials with three molecules.

  February 5, 2018

   · 

  3 min read
• BioCapital

  CEL-SCI to Present at 2018 BIO CEO & Investor Conference

  CEL-SCI announced that Geert Kersten, Chief Executive Officer, will be presenting at the 2018 BIO CEO & Investor Conference on Tuesday, February 13, 2018 at 9:45 a.m.

  February 5, 2018

   · 

  1 min read
• Business

  Insilico Medicine and Juvenescence Announce First Drug Candidate for Their Joint Venture Company Juvenescence.AI

  Juvenescence Limited announces that Juvenescence.AI, its joint venture with Insilico Medicine, Inc. (“Insilico”), has licensed its first compound family for clinical development.

  February 5, 2018

   · 

  3 min read
• Intellegens Secures First Commercial Contract for Alchemite Technology

  The potential of Intellegens’ Alchemite AI technology has been demonstrated with the recent announcement of a commercial collaboration between the Cambridge-based company and e-Therapeutics.

  February 5, 2018

   · 

  2 min read
• Biotech Beach

  Metagenics Joins the UC San Diego Center for Microbiome Innovation as an Industry Sponsor

  Metagenics has joined the UC San Diego Center for Microbiome Innovation as an industry sponsor.

  February 5, 2018

   · 

  3 min read
• Business

  Anavex Life Sciences to Announce Fiscal First Quarter 2018 Financial Results and Provide an Update on Clinical Programs and Corporate Highlights on Wednesday, February 7, 2018

  Management will host a conference call on Wednesday, February 7, 2018 at 4:30pm Eastern Time to review financial results and provide an update on its Clinical Programs.

  February 5, 2018

   · 

  3 min read
• BioMidwest

  miRagen Therapeutics Announces Proposed Public Offering of Common Stock

  All of the common stock is being offered by miRagen

  February 5, 2018

   · 

  6 min read
• Business

  Medigene AG: ‘Deutsche Krebshilfe Preis’ Awarded to Professor Dolores Schendel

  From 1998 to 2013, Professor Schendel was Director of the Institute of Molecular Immunology at the Helmholtz Zentrum München.

  February 5, 2018

   · 

  2 min read